Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AdipoGenix and Unigen Pharmaceuticals have entered into an agreement for the joint discovery and development of natural products that target human fat.
Subscribe to our email newsletter
AdipoGenix is a biopharmaceutical company developing small molecule therapies for obesity, type 2 diabetes and associated morbidities, and Unigen is a leading natural products R&D facility and supplier of proprietary, biologically active plant-derived ingredients to the natural products and pharmaceutical industries.
Under the terms of the agreement, AdipoGenix and Unigen will equally share in the costs and profits for the discovery, development, and commercialization of products resulting from the collaboration.
AdipoGenix will apply its proprietary human fat cell-based technologies to discover natural substances that reduce the fat content of human fat cells from Unigen’s collection of medicinal plant extracts.
Unigen will identify and produce active molecules from active extracts that are discovered and AdipoGenix will characterize mechanisms of action and molecular targets for active molecules taken into development.
AdipoGenix will retain world wide rights for the development and commercialization of any pharmaceutical products, and Unigen will retain world wide rights for the commercialization of any cosmeceutical or nutraceutical products that result from the collaboration.
“Unigen has an extensive collection of extracts from medicinal plants from around the world. Through this collaboration, we gain access to a unique source of natural substances, and expand our opportunities to discover and develop novel pharmaceuticals that reduce the fat content of human fat cells,” said Dr Ed Cannon, CEO of AdipoGenix.